

MediEscortChina

医疗突破与发展报告

China Medical Innovation & Breakthrough Report

2025 Edition

Disclaimer: This report is for reference only. Product availability, pricing, and clinical status may change. Please verify with individual hospitals and manufacturers for the most current information.

China Medical Innovation & Breakthrough Report

MediEscortChina Research Division | 2025 Edition

Part 1: Placidway Asia Chronic Disease Centers vs. China — Comparative Analysis

1.1 Leading Medical Centers in Asia (Chronic Disease Focus)

Based on Placidway platform data, the leading chronic disease treatment centers in Asia are distributed across:

Country/Region	Representative Institutions	Signature Programs
Thailand	Bangkok Hospital, Bumrungrad International	Cardiac rehab, diabetes management, anti-aging
India	Apollo Hospitals, Fortis Healthcare	Cardiovascular, dialysis, orthopedic replacement
Singapore	Mount Elizabeth, Raffles Hospital	Precision oncology, neurosurgery, organ transplant
Malaysia	Prince Court, Gleneagles KL	Cardiac surgery, IVF, health checkups
South Korea	Severance Hospital, Samsung Medical	Cancer therapy, plastic surgery, stem cells
Japan	Tokyo Medical University Hospital	Regenerative medicine, proton therapy, precision health screening
China	PUMC, Ruijin Hospital, West China Hospital	Full-spectrum coverage, significant price advantage

Thailand	Bangkok Hospital, Bumrungrad International	Cardiac rehab, diabetes management, anti-aging
India	Apollo Hospitals, Fortis Healthcare	Cardiovascular, dialysis, orthopedic replacement
Singapore	Mount Elizabeth, Raffles Hospital	Precision oncology, neurosurgery, organ transplant
Malaysia	Prince Court, Gleneagles KL	Cardiac surgery, IVF, health checkups
South Korea	Severance Hospital, Samsung Medical	Cancer therapy, plastic surgery, stem cells
Japan	Tokyo Medical University Hospital	Regenerative medicine, proton therapy, precision health screening
China	PUMC, Ruijin Hospital, West China Hospital	Full-spectrum coverage, significant price advantage

Thailand	Bangkok Hospital, Bumrungrad International	Cardiac rehab, diabetes management, anti-aging
India	Apollo Hospitals, Fortis Healthcare	Cardiovascular, dialysis, orthopedic replacement
Singapore	Mount Elizabeth, Raffles Hospital	Precision oncology, neurosurgery, organ transplant
Malaysia	Prince Court, Gleneagles KL	Cardiac surgery, IVF, health checkups
South Korea	Severance Hospital, Samsung Medical	Cancer therapy, plastic surgery, stem cells
Japan	Tokyo Medical University Hospital	Regenerative medicine, proton therapy, precision health screening
China	PUMC, Ruijin Hospital, West China Hospital	Full-spectrum coverage, significant price advantage

India	Apollo Hospitals, Fortis Healthcare	Cardiovascular, dialysis, orthopedic replacement
Singapore	Mount Elizabeth, Raffles Hospital	Precision oncology, neurosurgery, organ transplant
Malaysia	Prince Court, Gleneagles KL	Cardiac surgery, IVF, health checkups
South Korea	Severance Hospital, Samsung Medical	Cancer therapy, plastic surgery, stem cells
Japan	Tokyo Medical University Hospital	Regenerative medicine, proton therapy, precision health screening
China	PUMC, Ruijin Hospital, West China Hospital	Full-spectrum coverage, significant price advantage

Singapore	Mount Elizabeth, Raffles Hospital	Precision oncology, neurosurgery, organ transplant
Malaysia	Prince Court, Gleneagles KL	Cardiac surgery, IVF, health checkups
South Korea	Severance Hospital, Samsung Medical	Cancer therapy, plastic surgery, stem cells
Japan	Tokyo Medical University Hospital	Regenerative medicine, proton therapy, precision health screening
China	PUMC, Ruijin Hospital, West China Hospital	Full-spectrum coverage, significant price advantage

Malaysia	Prince Court, Gleneagles KL	Cardiac surgery, IVF, health checkups
South Korea	Severance Hospital, Samsung Medical	Cancer therapy, plastic surgery, stem cells
Japan	Tokyo Medical University Hospital	Regenerative medicine, proton therapy, precision health screening
China	PUMC, Ruijin Hospital, West China Hospital	Full-spectrum coverage, significant price advantage

South Korea	Severance Hospital, Samsung Medical	Cancer therapy, plastic surgery, stem cells
Japan	Tokyo Medical University Hospital	Regenerative medicine, proton therapy, precision health screening
China	PUMC, Ruijin Hospital, West China Hospital	Full-spectrum coverage, significant price advantage

Japan	Tokyo Medical University Hospital	Regenerative medicine, proton therapy, precision health screening
China	PUMC, Ruijin Hospital, West China Hospital	Full-spectrum coverage, significant price advantage

1.2 Overlap Analysis with MediEscortChina's 370-Item Catalog

A. Fully Overlapping Services (China Offers Equal or Higher Quality)

Based on Placidway Asia chronic disease center data, the following internationally sought-after procedures are all available in China at competitive pricing:

International Hot Service	Placidway Asia Representative	China Equivalent	China Price Advantage	Recommended Hospital
Stem Cell Therapy	Vega Stem Cell Clinic (Bangkok)	Umbilical/Adipose MSC Therapy	Save 40-60%	Peking University People's Hospital / Tianjin Hematology
Cardiac Bypass/Stent	Bumrungrad (Thailand)	Coronary Angiography + Stenting	1/10 of US price	Fuwai Hospital / Zhongshan Hospital
Knee Replacement	Apollo (India)	Total Knee Replacement (TKR)	Save 60-80%	Jishuitan Hospital / West China Orthopedics
Proton/Ion Therapy	NIRS (Japan)	Proton & Heavy-Ion Radiotherapy	Lower cost + shorter wait	Shanghai Proton / Wuwei Ion Center
IVF / Fertility	Jetanin (Thailand)	ART (IVF/ICSI)	Save 50-70%	Peking University Third Hospital / Shanghai Ninth
Health Checkup Packages	Japan Precision Screening	17 Departments, 370 Items	1/5 of Japan's price	PUMC / 301 Hospital
Dental Implants	Bangkok Dental Hospital	Korean/EU Brand Implants	Save 70%	Peking University Dental / West China Dental
Cataract Surgery	Singapore SNEC	Phaco + IOL Implantation	Save 80%	Zhongshan Ophthalmic / Tongren Eye
Parkinson's DBS	Medanta (India)	Deep Brain Stimulation (DBS)	Save 50%	Beijing Tiantan / Xuanwu Hospital
CAR-T Therapy	Singapore NUH	Chimeric Antigen Receptor T-Cell	Comparable price, equal technology	Ruijin Hospital / Peking University Cancer

Stem Cell Therapy	Vega Stem Cell Clinic (Bangkok)	Umbilical/Adipose MSC Therapy	Save 40-60%	Peking University People's Hospital / Tianjin Hematology
Cardiac Bypass/Stent	Bumrungrad (Thailand)	Coronary Angiography + Stenting	1/10 of US price	Fuwai Hospital / Zhongshan Hospital
Knee Replacement	Apollo (India)	Total Knee Replacement (TKR)	Save 60-80%	Jishuitan Hospital / West China Orthopedics
Proton/Ion Therapy	NIRS (Japan)	Proton & Heavy-Ion Radiotherapy	Lower cost + shorter wait	Shanghai Proton / Wuwei Ion Center
IVF / Fertility	Jetanin (Thailand)	ART (IVF/ICSI)	Save 50-70%	Peking University Third Hospital / Shanghai Ninth
Health Checkup Packages	Japan Precision Screening	17 Departments, 370 Items	1/5 of Japan's price	PUMC / 301 Hospital
Dental Implants	Bangkok Dental Hospital	Korean/EU Brand Implants	Save 70%	Peking University Dental / West China Dental
Cataract Surgery	Singapore SNEC	Phaco + IOL Implantation	Save 80%	Zhongshan Ophthalmic / Tongren Eye
Parkinson's DBS	Medanta (India)	Deep Brain Stimulation (DBS)	Save 50%	Beijing Tiantan / Xuanwu Hospital
CAR-T Therapy	Singapore NUH	Chimeric Antigen Receptor T-Cell	Comparable price, equal technology	Ruijin Hospital / Peking University Cancer

Stem Cell Therapy	Vega Stem Cell Clinic (Bangkok)	Umbilical/Adipose MSC Therapy	Save 40-60%	Peking University People's Hospital / Tianjin Hematology
Cardiac Bypass/Stent	Bumrungrad (Thailand)	Coronary Angiography + Stenting	1/10 of US price	Fuwai Hospital / Zhongshan Hospital
Knee Replacement	Apollo (India)	Total Knee Replacement (TKR)	Save 60-80%	Jishuitan Hospital / West China Orthopedics
Proton/Ion Therapy	NIRS (Japan)	Proton & Heavy-Ion Radiotherapy	Lower cost + shorter wait	Shanghai Proton / Wuwei Ion Center
IVF / Fertility	Jetanin (Thailand)	ART (IVF/ICSI)	Save 50-70%	Peking University Third Hospital / Shanghai Ninth
Health Checkup Packages	Japan Precision Screening	17 Departments, 370 Items	1/5 of Japan's price	PUMC / 301 Hospital
Dental Implants	Bangkok Dental Hospital	Korean/EU Brand Implants	Save 70%	Peking University Dental / West China Dental
Cataract Surgery	Singapore SNEC	Phaco + IOL Implantation	Save 80%	Zhongshan Ophthalmic / Tongren Eye
Parkinson's DBS	Medanta (India)	Deep Brain Stimulation (DBS)	Save 50%	Beijing Tiantan / Xuanwu Hospital
CAR-T Therapy	Singapore NUH	Chimeric Antigen Receptor T-Cell	Comparable price, equal technology	Ruijin Hospital / Peking University Cancer

Cardiac Bypass/Stent	Bumrungrad (Thailand)	Coronary Angiography + Stenting	1/10 of US price	Fuwai Hospital / Zhongshan Hospital
Knee Replacement	Apollo (India)	Total Knee Replacement (TKR)	Save 60-80%	Jishuitan Hospital / West China Orthopedics
Proton/Ion Therapy	NIRS (Japan)	Proton & Heavy-Ion Radiotherapy	Lower cost + shorter wait	Shanghai Proton / Wuwei Ion Center
IVF / Fertility	Jetanin (Thailand)	ART (IVF/ICSI)	Save 50-70%	Peking University Third Hospital / Shanghai Ninth
Health Checkup Packages	Japan Precision Screening	17 Departments, 370 Items	1/5 of Japan's price	PUMC / 301 Hospital
Dental Implants	Bangkok Dental Hospital	Korean/EU Brand Implants	Save 70%	Peking University Dental / West China Dental
Cataract Surgery	Singapore SNEC	Phaco + IOL Implantation	Save 80%	Zhongshan Ophthalmic / Tongren Eye
Parkinson's DBS	Medanta (India)	Deep Brain Stimulation (DBS)	Save 50%	Beijing Tiantan / Xuanwu Hospital
CAR-T Therapy	Singapore NUH	Chimeric Antigen Receptor T-Cell	Comparable price, equal technology	Ruijin Hospital / Peking University Cancer

Knee Replacement	Apollo (India)	Total Knee Replacement (TKR)	Save 60-80%	Jishuitan Hospital / West China Orthopedics
Proton/Ion Therapy	NIRS (Japan)	Proton & Heavy-Ion Radiotherapy	Lower cost + shorter wait	Shanghai Proton / Wuwei Ion Center
IVF / Fertility	Jetanin (Thailand)	ART (IVF/ICSI)	Save 50-70%	Peking University Third Hospital / Shanghai Ninth
Health Checkup Packages	Japan Precision Screening	17 Departments, 370 Items	1/5 of Japan's price	PUMC / 301 Hospital
Dental Implants	Bangkok Dental Hospital	Korean/EU Brand Implants	Save 70%	Peking University Dental / West China Dental
Cataract Surgery	Singapore SNEC	Phaco + IOL Implantation	Save 80%	Zhongshan Ophthalmic / Tongren Eye
Parkinson's DBS	Medanta (India)	Deep Brain Stimulation (DBS)	Save 50%	Beijing Tiantan / Xuanwu Hospital
CAR-T Therapy	Singapore NUH	Chimeric Antigen Receptor T-Cell	Comparable price, equal technology	Ruijin Hospital / Peking University Cancer

Proton/Ion Therapy	NIRS (Japan)	Proton & Heavy-Ion Radiotherapy	Lower cost + shorter wait	Shanghai Proton / Wuwei Ion Center
IVF / Fertility	Jetanin (Thailand)	ART (IVF/ICSI)	Save 50-70%	Peking University Third Hospital / Shanghai Ninth
Health Checkup Packages	Japan Precision Screening	17 Departments, 370 Items	1/5 of Japan's price	PUMC / 301 Hospital
Dental Implants	Bangkok Dental Hospital	Korean/EU Brand Implants	Save 70%	Peking University Dental / West China Dental
Cataract Surgery	Singapore SNEC	Phaco + IOL Implantation	Save 80%	Zhongshan Ophthalmic / Tongren Eye
Parkinson's DBS	Medanta (India)	Deep Brain Stimulation (DBS)	Save 50%	Beijing Tiantan / Xuanwu Hospital
CAR-T Therapy	Singapore NUH	Chimeric Antigen Receptor T-Cell	Comparable price, equal technology	Ruijin Hospital / Peking University Cancer

IVF / Fertility	Jetanin (Thailand)	ART (IVF/ICSI)	Save 50-70%	Peking University Third Hospital / Shanghai Ninth
Health Checkup Packages	Japan Precision Screening	17 Departments, 370 Items	1/5 of Japan's price	PUMC / 301 Hospital
Dental Implants	Bangkok Dental Hospital	Korean/EU Brand Implants	Save 70%	Peking University Dental / West China Dental
Cataract Surgery	Singapore SNEC	Phaco + IOL Implantation	Save 80%	Zhongshan Ophthalmic / Tongren Eye
Parkinson's DBS	Medanta (India)	Deep Brain Stimulation (DBS)	Save 50%	Beijing Tiantan / Xuanwu Hospital
CAR-T Therapy	Singapore NUH	Chimeric Antigen Receptor T-Cell	Comparable price, equal technology	Ruijin Hospital / Peking University Cancer

Health Checkup Packages	Japan Precision Screening	17 Departments, 370 Items	1/5 of Japan's price	PUMC / 301 Hospital
Dental Implants	Bangkok Dental Hospital	Korean/EU Brand Implants	Save 70%	Peking University Dental / West China Dental
Cataract Surgery	Singapore SNEC	Phaco + IOL Implantation	Save 80%	Zhongshan Ophthalmic / Tongren Eye
Parkinson's DBS	Medanta (India)	Deep Brain Stimulation (DBS)	Save 50%	Beijing Tiantan / Xuanwu Hospital
CAR-T Therapy	Singapore NUH	Chimeric Antigen Receptor T-Cell	Comparable price, equal technology	Ruijin Hospital / Peking University Cancer

Dental Implants	Bangkok Dental Hospital	Korean/EU Brand Implants	Save 70%	Peking University Dental / West China Dental
Cataract Surgery	Singapore SNEC	Phaco + IOL Implantation	Save 80%	Zhongshan Ophthalmic / Tongren Eye
Parkinson's DBS	Medanta (India)	Deep Brain Stimulation (DBS)	Save 50%	Beijing Tiantan / Xuanwu Hospital
CAR-T Therapy	Singapore NUH	Chimeric Antigen Receptor T-Cell	Comparable price, equal technology	Ruijin Hospital / Peking University Cancer

Cataract Surgery	Singapore SNEC	Phaco + IOL Implantation	Save 80%	Zhongshan Ophthalmic / Tongren Eye
Parkinson's DBS	Medanta (India)	Deep Brain Stimulation (DBS)	Save 50%	Beijing Tiantan / Xuanwu Hospital
CAR-T Therapy	Singapore NUH	Chimeric Antigen Receptor T-Cell	Comparable price, equal technology	Ruijin Hospital / Peking University Cancer

Parkinson's DBS	Medanta (India)	Deep Brain Stimulation (DBS)	Save 50%	Beijing Tiantan / Xuanwu Hospital
CAR-T Therapy	Singapore NUH	Chimeric Antigen Receptor T-Cell	Comparable price, equal technology	Ruijin Hospital / Peking University Cancer

B. Areas Where China Is Relatively Less Developed (Placidway Advantages)

Domain	Notes	China Status
Biological Rhythm / Anti-Aging Therapy	More developed in Thailand, Japan	Just starting, market to be developed
Psychedelic-Assisted Therapy	Not yet available in China	Regulatory restrictions
Medical Cannabis / CBD Treatment	Thailand has legalized	Strictly controlled
Luxury Wellness Resort-Style Medical Care	Japan, Thailand offer superior experience	Hospital-centric model; wellness resorts emerging

Biological Rhythm / Anti-Aging Therapy	More developed in Thailand, Japan	Just starting, market to be developed
Psychedelic-Assisted Therapy	Not yet available in China	Regulatory restrictions
Medical Cannabis / CBD Treatment	Thailand has legalized	Strictly controlled
Luxury Wellness Resort-Style Medical Care	Japan, Thailand offer superior experience	Hospital-centric model; wellness resorts emerging

Biological Rhythm / Anti-Aging Therapy	More developed in Thailand, Japan	Just starting, market to be developed
Psychedelic-Assisted Therapy	Not yet available in China	Regulatory restrictions
Medical Cannabis / CBD Treatment	Thailand has legalized	Strictly controlled
Luxury Wellness Resort-Style Medical Care	Japan, Thailand offer superior experience	Hospital-centric model; wellness resorts emerging

Psychedelic-Assisted Therapy	Not yet available in China	Regulatory restrictions
Medical Cannabis / CBD Treatment	Thailand has legalized	Strictly controlled
Luxury Wellness Resort-Style Medical Care	Japan, Thailand offer superior experience	Hospital-centric model; wellness resorts emerging

Medical Cannabis / CBD Treatment	Thailand has legalized	Strictly controlled
Luxury Wellness Resort-Style Medical Care	Japan, Thailand offer superior experience	Hospital-centric model; wellness resorts emerging

C. China-Unique / World-Leading Services Not Found on Placidway Asia

Service Category	China Distinctive Feature	Global Position
Traditional Chinese Medicine (TCM)	Constitution diagnosis, acupuncture, tuina, herbal paste	Globally unique, irreplaceable
Fecal Microbiota Transplantation (FMT)	Gut microbiota reconstruction	Leading in select indications
5G Remote Robotic Surgery	Real-time cross-regional robotic control	World's first successful cases
Integrated Chinese-Western Oncology Rehabilitation	Chemo/radiation toxicity reduction	Distinctive advantage
Large-Scale Precision Health Screening	Low price, high efficiency, full-department	Best cost-performance globally

Traditional Chinese Medicine (TCM)	Constitution diagnosis, acupuncture, tuina, herbal paste	Globally unique, irreplaceable
Fecal Microbiota Transplantation (FMT)	Gut microbiota reconstruction	Leading in select indications
5G Remote Robotic Surgery	Real-time cross-regional robotic control	World's first successful cases
Integrated Chinese-Western Oncology Rehabilitation	Chemo/radiation toxicity reduction	Distinctive advantage
Large-Scale Precision Health Screening	Low price, high efficiency, full-department	Best cost-performance globally

Traditional Chinese Medicine (TCM)	Constitution diagnosis, acupuncture, tuina, herbal paste	Globally unique, irreplaceable
Fecal Microbiota Transplantation (FMT)	Gut microbiota reconstruction	Leading in select indications
5G Remote Robotic Surgery	Real-time cross-regional robotic control	World's first successful cases
Integrated Chinese-Western Oncology Rehabilitation	Chemo/radiation toxicity reduction	Distinctive advantage
Large-Scale Precision Health Screening	Low price, high efficiency, full-department	Best cost-performance globally

Fecal Microbiota Transplantation (FMT)	Gut microbiota reconstruction	Leading in select indications
5G Remote Robotic Surgery	Real-time cross-regional robotic control	World's first successful cases
Integrated Chinese-Western Oncology Rehabilitation	Chemo/radiation toxicity reduction	Distinctive advantage
Large-Scale Precision Health Screening	Low price, high efficiency, full-department	Best cost-performance globally

5G Remote Robotic Surgery	Real-time cross-regional robotic control	World's first successful cases
Integrated Chinese-Western Oncology Rehabilitation	Chemo/radiation toxicity reduction	Distinctive advantage
Large-Scale Precision Health Screening	Low price, high efficiency, full-department	Best cost-performance globally

Integrated Chinese-Western Oncology Rehabilitation	Chemo/radiation toxicity reduction	Distinctive advantage
Large-Scale Precision Health Screening	Low price, high efficiency, full-department	Best cost-performance globally

Part 2: China's Medical Breakthroughs — Feature Article

From "Follower" to "Peer" and Even "Leader" — The Global Rise of China's Medical Innovation

Introduction

While the world still debates the "cost-effectiveness" of medical tourism, China has already completed its leap from "medical destination" to "medical innovation hub." From the precision medicine laboratories at Peking Union Medical College Hospital to the biopharmaceutical bases in Shanghai Zhangjiang Hi-Tech Park, from AI medical imaging companies in Shenzhen Bay to the Tianfu International Bio-Town in Chengdu, China's medical industry is achieving breakthroughs at a pace that commands global attention.

1. Regenerative Medicine & Stem Cells: Standing on the World Stage

China has moved from follower to peer in stem cell research. By 2024, the number of stem cell clinical research filing institutions in China has reached 140+, covering neurological disorders, cardiovascular disease, autoimmune diseases, and more.

Breakthrough Highlights:

- Mesenchymal Stem Cell Therapy for Knee Osteoarthritis: Entered Phase III clinical trials, conducted at multiple top-tier hospitals
- Cord Blood Stem Cell Therapy for Cerebral Palsy: Beijing Armed Police General Hospital and Shanghai Children's Medical Center have published significant clinical cases
- iPSC Induced Pluripotent Stem Cells: Companies such as Zhongsheng Suyuan and Huide Bio are advancing, with several pipelines entering clinical trials

2. Cancer Immunotherapy: The Chinese Power of CAR-T

China has become a major force in global CAR-T cell therapy. As of 2025, five CAR-T products have been approved for marketing in China, covering leukemia, lymphoma, and multiple myeloma.

Representative Breakthroughs:

- Fosun Kite: Introduced Yescarta technology and localized production
- JW Therapeutics (药明巨诺): Relma-cel (倍诺达) approved for relapsed/refractory large B-cell lymphoma
- Legend Biotech: Partnered with Johnson & Johnson; Carvykti approved in the US, EU, and China
- Carsgen Therapeutics (科济药业): World's first solid-tumor CAR-T entering clinical trials for gastric and pancreatic cancer

3. Precision Medicine & Genetic Testing: The Era of Accessibility

China's genetic testing costs have dropped to the lowest globally. Whole-exome sequencing prices have fallen below ¥2,000 RMB, and NGS tumor panel testing has been included in medical insurance in multiple regions.

Core Progress:

- BGI (华大基因): Built the world's largest genomics data center
- Burning Rock (燃石医学): MRD minimal residual disease detection technology is internationally leading
- Geneseeq (世和基因): Early-screening products received FDA Breakthrough Device designation

4. AI Medicine: From Diagnostic Assistance to Surgical Robots

China has formed a complete AI medical imaging industry chain. Companies such as InferVision, Shukun Technology, and Airdoc have received FDA/CE/NMPA triple certification for their products.

Milestone Events:

- MicroPort (微创医疗): Toumai laparoscopic surgical robot received NMPA approval, breaking the da Vinci monopoly
- Edge Medical (精锋医疗): Multi-port/single-port surgical robots entering clinical use
- TINAVI (天智航): Orthopedic surgical robot has completed 10,000+ operations

5. Modernization of Traditional Chinese Medicine: A Chinese Solution Going Global

TCM is transitioning from "empirical medicine" to "evidence-based medicine." Products such as Lianhua Qingwen, Artemisinin, and Compound Danshen Dripping Pills have completed international multicenter clinical trials.

Internationalization Progress:

- WHO officially included traditional medicine in ICD-11 (International Classification of Diseases, 11th Revision)
- TCM has spread to 196 countries and regions
- 70+ countries have signed TCM cooperation agreements

Part 3: Market-Ready / Clinical-Stage Product & Service Catalog

3.1 CAR-T Cell Therapy Products (Marketed / Clinical Stage)

Product Name	Company	Target	Indication	Approval Status	Reference Price	Partner Hospitals
Yescarta (奕凯达)	Fosun Kite	CD19	Relapsed/R efractory Large B-Cell Lymphoma	Marketed (NMPA 2021)	¥1,200,000	Ruijin Hospital, Peking University Cancer Hospital, Jiangsu Provincial People's Hospital
Relma-cel (倍诺达)	JW Therapeutics	CD19	Relapsed/R efractory Large B-Cell Lymphoma	Marketed (NMPA 2021)	¥1,290,000	Ruijin Hospital, Tianjin Cancer Hospital
Fucaso (福可苏)	IBI / Legend Biotech	BCMA	Relapsed/R efractory Multiple Myeloma	Marketed (NMPA 2023)	¥1,160,000	Beijing Chaoyang Hospital, Zhejiang University First Affiliated Hospital
CT041 (赛恺泽)	Carsgen Therapeutics	CLDN18.2	Gastric / Gastroesophageal Junction Cancer (Solid Tumor)	Phase II	TBD	Sun Yat-sen University Cancer Center, Peking University Cancer Hospital
IBI346	Innovent / Roche	CD19	Follicular Lymphoma	Phase III	TBD	Multi-center
CT0180	Carsgen Therapeutics	BCMA	Multiple Myeloma (Allogeneic/Off-the-Shelf)	Phase I	TBD	Multi-center

Yescarta (奕凯达)	Fosun Kite	CD19	Relapsed/R efractory Large B-Cell Lymphoma	Marketed (NMPA 2021)	¥1,200,000	Ruijin Hospital, Peking University Cancer Hospital, Jiangsu Provincial People's Hospital
Relma-cel (倍诺达)	JW Therape utics	CD19	Relapsed/R efractory Large B-Cell Lymphoma	Marketed (NMPA 2021)	¥1,290,000	Ruijin Hospital, Tianjin Cancer Hospital
Fucaso (福可苏)	IBI / Legend Biotech	BCMA	Relapsed/R efractory Multiple Myeloma	Marketed (NMPA 2023)	¥1,160,000	Beijing Chaoyang Hospital, Zhejiang University First Affiliated Hospital
CT041 (赛恺泽)	Carsgen Th erapeutics	CLDN18.2	Gastric / Ga stroesophag eal Junction Cancer (Solid Tumor)	Phase II	TBD	Sun Yat-sen University Cancer Center, Peking University Cancer Hospital
IBI346	Innovent / Roche	CD19	Follicular Lymphoma	Phase III	TBD	Multi-center
CT0180	Carsgen Th erapeutics	BCMA	Multiple Myeloma (Al logeneic/Off- the-Shelf)	Phase I	TBD	Multi-center

Yescarta (奕凯达)	Fosun Kite	CD19	Relapsed/R efractory Large B-Cell Lymphoma	Marketed (NMPA 2021)	¥1,200,000	Ruijin Hospital, Peking University Cancer Hospital, Jiangsu Provincial People's Hospital
Relma-cel (倍诺达)	JW Therape utics	CD19	Relapsed/R efractory Large B-Cell Lymphoma	Marketed (NMPA 2021)	¥1,290,000	Ruijin Hospital, Tianjin Cancer Hospital
Fucaso (福可苏)	IBI / Legend Biotech	BCMA	Relapsed/R efractory Multiple Myeloma	Marketed (NMPA 2023)	¥1,160,000	Beijing Chaoyang Hospital, Zhejiang University First Affiliated Hospital
CT041 (赛恺泽)	Carsgen Th erapeutics	CLDN18.2	Gastric / Ga stroesophag eal Junction Cancer (Solid Tumor)	Phase II	TBD	Sun Yat-sen University Cancer Center, Peking University Cancer Hospital
IBI346	Innovent / Roche	CD19	Follicular Lymphoma	Phase III	TBD	Multi-center
CT0180	Carsgen Th erapeutics	BCMA	Multiple Myeloma (Al logeneic/Off- the-Shelf)	Phase I	TBD	Multi-center

Relma-cel (倍诺达)	JW Therapeutics	CD19	Relapsed/Refractory Large B-Cell Lymphoma	Marketed (NMPA 2021)	¥1,290,000	Ruijin Hospital, Tianjin Cancer Hospital
Fucaso (福可苏)	IBI / Legend Biotech	BCMA	Relapsed/Refractory Multiple Myeloma	Marketed (NMPA 2023)	¥1,160,000	Beijing Chaoyang Hospital, Zhejiang University First Affiliated Hospital
CT041 (赛恺泽)	Carsgen Therapeutics	CLDN18.2	Gastric / Gastroesophageal Junction Cancer (Solid Tumor)	Phase II	TBD	Sun Yat-sen University Cancer Center, Peking University Cancer Hospital
IBI346	Innovent / Roche	CD19	Follicular Lymphoma	Phase III	TBD	Multi-center
CT0180	Carsgen Therapeutics	BCMA	Multiple Myeloma (Allogeneic/Off-the-Shelf)	Phase I	TBD	Multi-center

Fucaso (福可苏)	IBI / Legend Biotech	BCMA	Relapsed/R efractory Multiple Myeloma	Marketed (NMPA 2023)	¥1,160,000	Beijing Chaoyang Hospital, Zhejiang University First Affiliated Hospital
CT041 (赛恺泽)	Carsgen Th erapeutics	CLDN18.2	Gastric / Ga stroesophag eal Junction Cancer (Solid Tumor)	Phase II	TBD	Sun Yat-sen University Cancer Center, Peking University Cancer Hospital
IBI346	Innovent / Roche	CD19	Follicular Lymphoma	Phase III	TBD	Multi-center
CT0180	Carsgen Th erapeutics	BCMA	Multiple Myeloma (Al logeneic/Off- the-Shelf)	Phase I	TBD	Multi-center

CT041 (赛恺泽)	Carsgen Th erapeutics	CLDN18.2	Gastric / Ga stroesophag eal Junction Cancer (Solid Tumor)	Phase II	TBD	Sun Yat-sen University Cancer Center, Peking University Cancer Hospital
IBI346	Innovent / Roche	CD19	Follicular Lymphoma	Phase III	TBD	Multi-center
CT0180	Carsgen Th erapeutics	BCMA	Multiple Myeloma (Al logeneic/Off- the-Shelf)	Phase I	TBD	Multi-center

IBI346	Innovent / Roche	CD19	Follicular Lymphoma	Phase III	TBD	Multi-center
CT0180	Carsgen Therapeutics	BCMA	Multiple Myeloma (Allogeneic/Off-the-Shelf)	Phase I	TBD	Multi-center

Technical Highlights: China's CAR-T field has moved from "follower" to "peer." Legend Biotech's Carvykti received approval from the FDA, EMA, and NMPA — the first original Chinese CAR-T product to achieve global market access.

Recommended Physicians:

- Prof. Wei-Li Zhao (赵维莅) — Director of Hematology, Ruijin Hospital; Principal Investigator of multiple CAR-T clinical trials
- Prof. Jun Zhu (朱军) — Director of Lymphoma, Peking University Cancer Hospital; lead author of China's lymphoma guidelines
- Prof. Xiao-Jun Huang (黄晓军) — Director of Hematology, Peking University People's Hospital; founder of the "Beijing Protocol" for haploidentical transplant

3.2 Surgical Robotic Systems (Marketed / Clinical Stage)

Product Name	Company	Type	NMPA Approval	Clinical Applications	Price Range	Installed Hospitals
Toumai (图迈)	MicroPort	Laparoscopic Surgical Robot (4-Arm)	2022	Urology, General Surgery, Gynecology	¥20-35M/unit	Ruijin, West China, Wuhan Tongji
MP1000 (精锋®多孔)	Edge Medical	Laparoscopic Surgical Robot	2023	Urology, Gynecology	¥20-30M/unit	Zhongshan First Affiliated, West China, Xiangya
SP1000 (精锋®单孔)	Edge Medical	Single-Port Laparoscopic Robot	2024	Urology, Gynecology	TBD	Clinical trials
TINAVI (天玑®)	TINAVI	Orthopedic Surgical Navigation Robot	2016	Spine, Trauma, Joint	¥15-25M/unit	Jishuitan, 301 Hospital, Xijing
Honghu (鸿鹄®)	MicroPort	Joint Replacement Robot	2022	Total Knee / Total Hip	¥12-20M/unit	Shanghai Sixth, West China
Miaoshou S (妙手S)	Tianjin University / Weigao	Laparoscopic Surgical Robot	2021	General Surgery, Urology	¥15-25M/unit	Tianjin Medical University General, Qilu Hospital
Kondo (康多®)	Hurw / SinoMedical	Laparoscopic Surgical Robot	2023	Urology	~¥20M/unit	Peking Union, Peking University First Hospital

Toumai (图迈)	MicroPort	Laparoscopic Surgical Robot (4-Arm)	2022	Urology, General Surgery, Gynecology	¥20-35M/unit	Ruijin, West China, Wuhan Tongji
MP1000 (精锋®多孔)	Edge Medical	Laparoscopic Surgical Robot	2023	Urology, Gynecology	¥20-30M/unit	Zhongshan First Affiliated, West China, Xiangya
SP1000 (精锋®单孔)	Edge Medical	Single-Port Laparoscopic Robot	2024	Urology, Gynecology	TBD	Clinical trials
TINAVI (天玑®)	TINAVI	Orthopedic Surgical Navigation Robot	2016	Spine, Trauma, Joint	¥15-25M/unit	Jishuitan, 301 Hospital, Xijing
Honghu (鸿鹄®)	MicroPort	Joint Replacement Robot	2022	Total Knee / Total Hip	¥12-20M/unit	Shanghai Sixth, West China
Miaoshou S (妙手S)	Tianjin University / Weigao	Laparoscopic Surgical Robot	2021	General Surgery, Urology	¥15-25M/unit	Tianjin Medical University General, Qilu Hospital
Kondo (康多®)	Hurw / SinoMedical	Laparoscopic Surgical Robot	2023	Urology	~¥20M/unit	Peking Union, Peking University First Hospital

Toumai (图迈)	MicroPort	Laparoscopic Surgical Robot (4-Arm)	2022	Urology, General Surgery, Gynecology	¥20-35M/unit	Ruijin, West China, Wuhan Tongji
MP1000 (精锋®多孔)	Edge Medical	Laparoscopic Surgical Robot	2023	Urology, Gynecology	¥20-30M/unit	Zhongshan First Affiliated, West China, Xiangya
SP1000 (精锋®单孔)	Edge Medical	Single-Port Laparoscopic Robot	2024	Urology, Gynecology	TBD	Clinical trials
TINAVI (天玑®)	TINAVI	Orthopedic Surgical Navigation Robot	2016	Spine, Trauma, Joint	¥15-25M/unit	Jishuitan, 301 Hospital, Xijing
Honghu (鸿鹄®)	MicroPort	Joint Replacement Robot	2022	Total Knee / Total Hip	¥12-20M/unit	Shanghai Sixth, West China
Miaoshou S (妙手S)	Tianjin University / Weigao	Laparoscopic Surgical Robot	2021	General Surgery, Urology	¥15-25M/unit	Tianjin Medical University General, Qilu Hospital
Kondo (康多®)	Hurw / SinoMedical	Laparoscopic Surgical Robot	2023	Urology	~¥20M/unit	Peking Union, Peking University First Hospital

MP1000 (精锋®多孔)	Edge Medical	Laparoscopic Surgical Robot	2023	Urology, Gynecology	¥20-30M/unit	Zhongshan First Affiliated, West China, Xiangya
SP1000 (精锋®单孔)	Edge Medical	Single-Port Laparoscopic Robot	2024	Urology, Gynecology	TBD	Clinical trials
TINAVI (天玑®)	TINAVI	Orthopedic Surgical Navigation Robot	2016	Spine, Trauma, Joint	¥15-25M/unit	Jishuitan, 301 Hospital, Xijing
Honghu (鸿鹄®)	MicroPort	Joint Replacement Robot	2022	Total Knee / Total Hip	¥12-20M/unit	Shanghai Sixth, West China
Miaoshou S (妙手S)	Tianjin University / Weigao	Laparoscopic Surgical Robot	2021	General Surgery, Urology	¥15-25M/unit	Tianjin Medical University General, Qilu Hospital
Kondo (康多®)	Hurw / SinoMedical	Laparoscopic Surgical Robot	2023	Urology	~¥20M/unit	Peking Union, Peking University First Hospital

SP1000 (精锋®单孔)	Edge Medical	Single-Port Laparoscopy Robot	2024	Urology, Gynecology	TBD	Clinical trials
TINAVI (天玑®)	TINAVI	Orthopedic Surgical Navigation Robot	2016	Spine, Trauma, Joint	¥15-25M/unit	Jishuitan, 301 Hospital, Xijing
Honghu (鸿鹄®)	MicroPort	Joint Replacement Robot	2022	Total Knee / Total Hip	¥12-20M/unit	Shanghai Sixth, West China
Miaoshou S (妙手S)	Tianjin University / Weigao	Laparoscopic Surgical Robot	2021	General Surgery, Urology	¥15-25M/unit	Tianjin Medical University General, Qilu Hospital
Kondo (康多®)	Hurw / SinoMedical	Laparoscopic Surgical Robot	2023	Urology	~¥20M/unit	Peking Union, Peking University First Hospital

TINAVI (天玑®)	TINAVI	Orthopedic Surgical Navigation Robot	2016	Spine, Trauma, Joint	¥15-25M/unit	Jishuitan, 301 Hospital, Xijing
Honghu (鸿鹄®)	MicroPort	Joint Replacement Robot	2022	Total Knee / Total Hip	¥12-20M/unit	Shanghai Sixth, West China
Miaoshou S (妙手S)	Tianjin University / Weigao	Laparoscopic Surgical Robot	2021	General Surgery, Urology	¥15-25M/unit	Tianjin Medical University General, Qilu Hospital
Kondo (康多®)	Hurw / SinoMedical	Laparoscopic Surgical Robot	2023	Urology	~¥20M/unit	Peking Union, Peking University First Hospital

Honghu (鸿鹄®)	MicroPort	Joint Replacement Robot	2022	Total Knee / Total Hip	¥12-20M/unit	Shanghai Sixth, West China
Miaoshou S (妙手S)	Tianjin University / Weigao	Laparoscopic Surgical Robot	2021	General Surgery, Urology	¥15-25M/unit	Tianjin Medical University General, Qilu Hospital
Kondo (康多®)	Hurw / SinoMedical	Laparoscopic Surgical Robot	2023	Urology	~¥20M/unit	Peking Union, Peking University First Hospital

Miaoshou S (妙手S)	Tianjin University / Weigao	Laparoscopic Surgical Robot	2021	General Surgery, Urology	¥15-25M/unit	Tianjin Medical University General, Qilu Hospital
Kondo (康多®)	Hurw / SinoMedical	Laparoscopic Surgical Robot	2023	Urology	~¥20M/unit	Peking Union, Peking University First Hospital

Technical Highlights: MicroPort's "Toumai" was the first domestically produced four-arm laparoscopic surgical robot to receive NMPA approval, breaking the long-standing monopoly of the American da Vinci system in China. As of 2025, the installed base of surgical robots in China has exceeded 500 units.

Recommended Physicians:

- Prof. Bai-Yong Shen (沈柏用) — Vice President of Ruijin Hospital; performed multiple Toumai robot-assisted pancreatic surgeries
- Prof. Qiang Wei (魏强) — Director of Urology, West China Hospital; expert in robot-assisted radical prostatectomy
- Prof. Lun-Xu Liu (刘伦旭) — Director of Thoracic Surgery, West China Hospital; pioneer in robotic lung cancer minimally invasive surgery
- Prof. Xu Zhang (张旭) — Academician, Chinese Academy of Engineering; Urology, 301 Hospital; leader in robotic surgery

3.3 Proton / Heavy-Ion Therapy Centers

Center Name	City	Equipment Type	Operational Status	Annual Capacity	Indications	Contact
Shanghai Proton and Heavy Ion Center	Shanghai Pudong	Proton + Carbon Ion (Siemens)	Operating since 2015	~1,000 cases/year	NPC, prostate, lung, liver, pancreatic	+86-21-382 9-6000
Gansu Wuwei Heavy Ion Center	Wuwei, Gansu	Carbon Ion (Domestic Device)	Operating since 2020	~500 cases/year	Multiple solid tumors	+86-935-61 8-2000
Shandong Cancer Hospital Proton Center	Jinan	Proton (Varian)	Operating since 2023	~800 cases/year	Head & neck, lung, esophageal	+86-531-67 62-6120
Hefei Ion Medical Center	Hefei, Anhui	Proton (Varian)	Expected 2025	~1,000 cases/year	Multiple cancers	+86-551-65 59-5000
Beijing Proton Medical Center	Beijing Fangshan	Proton (IBA)	Expected 2026	~1,500 cases/year	Multiple cancers	Under construction
Wuhan Proton Center	Wuhan, Hubei	Proton	Under construction	TBD	Multiple cancers	Under construction

Shanghai Proton and Heavy Ion Center	Shanghai Pudong	Proton + Carbon Ion (Siemens)	Operating since 2015	~1,000 cases/year	NPC, prostate, lung, liver, pancreatic	+86-21-382 9-6000
Gansu Wuwei Heavy Ion Center	Wuwei, Gansu	Carbon Ion (Domestic Device)	Operating since 2020	~500 cases/year	Multiple solid tumors	+86-935-61 8-2000
Shandong Cancer Hospital Proton Center	Jinan	Proton (Varian)	Operating since 2023	~800 cases/year	Head & neck, lung, esophageal	+86-531-67 62-6120
Hefei Ion Medical Center	Hefei, Anhui	Proton (Varian)	Expected 2025	~1,000 cases/year	Multiple cancers	+86-551-65 59-5000
Beijing Proton Medical Center	Beijing Fangshan	Proton (IBA)	Expected 2026	~1,500 cases/year	Multiple cancers	Under construction
Wuhan Proton Center	Wuhan, Hubei	Proton	Under construction	TBD	Multiple cancers	Under construction

Shanghai Proton and Heavy Ion Center	Shanghai Pudong	Proton + Carbon Ion (Siemens)	Operating since 2015	~1,000 cases/year	NPC, prostate, lung, liver, pancreatic	+86-21-382 9-6000
Gansu Wuwei Heavy Ion Center	Wuwei, Gansu	Carbon Ion (Domestic Device)	Operating since 2020	~500 cases/year	Multiple solid tumors	+86-935-61 8-2000
Shandong Cancer Hospital Proton Center	Jinan	Proton (Varian)	Operating since 2023	~800 cases/year	Head & neck, lung, esophageal	+86-531-67 62-6120
Hefei Ion Medical Center	Hefei, Anhui	Proton (Varian)	Expected 2025	~1,000 cases/year	Multiple cancers	+86-551-65 59-5000
Beijing Proton Medical Center	Beijing Fangshan	Proton (IBA)	Expected 2026	~1,500 cases/year	Multiple cancers	Under construction
Wuhan Proton Center	Wuhan, Hubei	Proton	Under construction	TBD	Multiple cancers	Under construction

Gansu Wuwei Heavy Ion Center	Wuwei, Gansu	Carbon Ion (Domestic Device)	Operating since 2020	~500 cases/year	Multiple solid tumors	+86-935-618-2000
Shandong Cancer Hospital Proton Center	Jinan	Proton (Varian)	Operating since 2023	~800 cases/year	Head & neck, lung, esophageal	+86-531-6762-6120
Hefei Ion Medical Center	Hefei, Anhui	Proton (Varian)	Expected 2025	~1,000 cases/year	Multiple cancers	+86-551-6559-5000
Beijing Proton Medical Center	Beijing Fangshan	Proton (IBA)	Expected 2026	~1,500 cases/year	Multiple cancers	Under construction
Wuhan Proton Center	Wuhan, Hubei	Proton	Under construction	TBD	Multiple cancers	Under construction

Shandong Cancer Hospital Proton Center	Jinan	Proton (Varian)	Operating since 2023	~800 cases/year	Head & neck, lung, esophageal	+86-531-6762-6120
Hefei Ion Medical Center	Hefei, Anhui	Proton (Varian)	Expected 2025	~1,000 cases/year	Multiple cancers	+86-551-6559-5000
Beijing Proton Medical Center	Beijing Fangshan	Proton (IBA)	Expected 2026	~1,500 cases/year	Multiple cancers	Under construction
Wuhan Proton Center	Wuhan, Hubei	Proton	Under construction	TBD	Multiple cancers	Under construction

Hefei Ion Medical Center	Hefei, Anhui	Proton (Varian)	Expected 2025	~1,000 cases/year	Multiple cancers	+86-551-6559-5000
Beijing Proton Medical Center	Beijing Fangshan	Proton (IBA)	Expected 2026	~1,500 cases/year	Multiple cancers	Under construction
Wuhan Proton Center	Wuhan, Hubei	Proton	Under construction	TBD	Multiple cancers	Under construction

Beijing Proton Medical Center	Beijing Fangshan	Proton (IBA)	Expected 2026	~1,500 cases/year	Multiple cancers	Under construction
Wuhan Proton Center	Wuhan, Hubei	Proton	Under construction	TBD	Multiple cancers	Under construction

Technical Highlights: The Wuwei Heavy Ion Center employs a medical heavy-ion accelerator independently developed by the Institute of Modern Physics, Chinese Academy of Sciences. It is China's first and the world's fourth registered carbon-ion therapy system, marking China as the fourth country globally to master heavy-ion therapy technology.

Recommended Physicians:

- Prof. Guo-Liang Jiang (蒋国梁) — Founding President of Shanghai Proton and Heavy Ion Center; pioneer of proton therapy in China
- Prof. Jia-De Lu (陆嘉德) — Clinical Director, Shanghai Proton and Heavy Ion Center; expert in NPC proton therapy
- Prof. Xiao-Hu Wang (王小虎) — President of Wuwei Heavy Ion Center; clinical expert in heavy-ion therapy

3.4 Stem Cell & Regenerative Medicine Products / Services

Product / Service	Company / Institution	Source	Indication	Clinical Stage	Partner Hospitals	Reference Price
Human Umbilical Cord MSC	HansCell / Zhongyuan Concord	Umbilical Cord	Knee OA, GVHD, SLE	Phase III / Approved (select indications)	Multi-center	¥30,000-80,000/course
Human Adipose MSC	Multiple Institutions	Autologous Fat	Facial rejuvenation, joint repair	Phase II	Private / Tertiary	¥20,000-100,000
iPSC-Derived Dopaminergic Neurons	Zhongsheng Suyuan	iPSC Induction	Parkinson's Disease	Phase I	Xuanwu Hospital, Xiangya	Clinical stage
iPSC-Derived Islet Cells	Huide Bio / Ruipu Chenchuang	iPSC Induction	Type 1 Diabetes	Phase I	Multi-center	Clinical stage
CARTISTE M®	Medipost (Korea, imported to China)	Cord Blood MSC	Knee OA cartilage defect	Marketed in Korea; China clinical	Beijing Jishuitan Hospital	¥50,000-100,000
PRP (Platelet-Rich Plasma)	Multiple Tertiary Hospitals	Autologous Blood	Sports injury, OA, wound repair	Routine clinical application	Peking University Third Hospital Sports Medicine	¥2,000-5,000/session

Human Umbilical Cord MSC	HansCell / Zhongyuan Concord	Umbilical Cord	Knee OA, GVHD, SLE	Phase III / Approved (select indications)	Multi-center	¥30,000-80,000/course
Human Adipose MSC	Multiple Institutions	Autologous Fat	Facial rejuvenation, joint repair	Phase II	Private / Tertiary	¥20,000-100,000
iPSC-Derived Dopaminergic Neurons	Zhongsheng Suyuan	iPSC Induction	Parkinson's Disease	Phase I	Xuanwu Hospital, Xiangya	Clinical stage
iPSC-Derived Islet Cells	Huide Bio / Ruipu Chenchuang	iPSC Induction	Type 1 Diabetes	Phase I	Multi-center	Clinical stage
CARTISTE M®	Medipost (Korea, imported to China)	Cord Blood MSC	Knee OA cartilage defect	Marketed in Korea; China clinical	Beijing Jishuitan Hospital	¥50,000-100,000
PRP (Platelet-Rich Plasma)	Multiple Tertiary Hospitals	Autologous Blood	Sports injury, OA, wound repair	Routine clinical application	Peking University Third Hospital Sports Medicine	¥2,000-5,000/session

Human Umbilical Cord MSC	HansCell / Zhongyuan Concord	Umbilical Cord	Knee OA, GVHD, SLE	Phase III / Approved (select indications)	Multi-center	¥30,000-80,000/course
Human Adipose MSC	Multiple Institutions	Autologous Fat	Facial rejuvenation, joint repair	Phase II	Private / Tertiary	¥20,000-100,000
iPSC-Derived Dopaminergic Neurons	Zhongsheng Suyuan	iPSC Induction	Parkinson's Disease	Phase I	Xuanwu Hospital, Xiangya	Clinical stage
iPSC-Derived Islet Cells	Huide Bio / Ruipu Chenchuang	iPSC Induction	Type 1 Diabetes	Phase I	Multi-center	Clinical stage
CARTISTE M®	Medipost (Korea, imported to China)	Cord Blood MSC	Knee OA cartilage defect	Marketed in Korea; China clinical	Beijing Jishuitan Hospital	¥50,000-100,000
PRP (Platelet-Rich Plasma)	Multiple Tertiary Hospitals	Autologous Blood	Sports injury, OA, wound repair	Routine clinical application	Peking University Third Hospital Sports Medicine	¥2,000-5,000/session

Human Adipose MSC	Multiple Institutions	Autologous Fat	Facial rejuvenation, joint repair	Phase II	Private / Tertiary	¥20,000-100,000
iPSC-Derived Dopamineergic Neurons	Zhongsheng Suyuan	iPSC Induction	Parkinson's Disease	Phase I	Xuanwu Hospital, Xiangya	Clinical stage
iPSC-Derived Islet Cells	Huide Bio / Ruipu Chenchuang	iPSC Induction	Type 1 Diabetes	Phase I	Multi-center	Clinical stage
CARTISTE M®	Medipost (Korea, imported to China)	Cord Blood MSC	Knee OA cartilage defect	Marketed in Korea; China clinical	Beijing Jishuitan Hospital	¥50,000-100,000
PRP (Platelet-Rich Plasma)	Multiple Tertiary Hospitals	Autologous Blood	Sports injury, OA, wound repair	Routine clinical application	Peking University Third Hospital Sports Medicine	¥2,000-5,000/session

iPSC-Derived Dopamineergic Neurons	Zhongsheng Suyuan	iPSC Induction	Parkinson's Disease	Phase I	Xuanwu Hospital, Xiangya	Clinical stage
iPSC-Derived Islet Cells	Huide Bio / Ruipu Chenchuang	iPSC Induction	Type 1 Diabetes	Phase I	Multi-center	Clinical stage
CARTISTE M®	Medipost (Korea, imported to China)	Cord Blood MSC	Knee OA cartilage defect	Marketed in Korea; China clinical	Beijing Jishuitan Hospital	¥50,000-100,000
PRP (Platelet-Rich Plasma)	Multiple Tertiary Hospitals	Autologous Blood	Sports injury, OA, wound repair	Routine clinical application	Peking University Third Hospital Sports Medicine	¥2,000-5,000/session

iPSC-Derived Islet Cells	Huide Bio / Ruipu Chenchuang	iPSC Induction	Type 1 Diabetes	Phase I	Multi-center	Clinical stage
CARTISTE M®	Medipost (Korea, imported to China)	Cord Blood MSC	Knee OA cartilage defect	Marketed in Korea; China clinical	Beijing Jishuitan Hospital	¥50,000-100,000
PRP (Platelet-Rich Plasma)	Multiple Tertiary Hospitals	Autologous Blood	Sports injury, OA, wound repair	Routine clinical application	Peking University Third Hospital Sports Medicine	¥2,000-5,000/session

CARTISTE M®	Medipost (Korea, imported to China)	Cord Blood MSC	Knee OA cartilage defect	Marketed in Korea; China clinical	Beijing Jishuitan Hospital	¥50,000-100,000
PRP (Platelet-Rich Plasma)	Multiple Tertiary Hospitals	Autologous Blood	Sports injury, OA, wound repair	Routine clinical application	Peking University Third Hospital Sports Medicine	¥2,000-5,000/session

Technical Highlights: China ranks second globally in the number of stem cell clinical research filings, behind only the United States. In 2024, the number of IND applications for stem cell new drugs in China continued to increase, covering neurology, cardiovascular, autoimmune diseases, and more.

Recommended Physicians / Institutions:

- Prof. Zhong-Chao Han (韩忠朝) — Chairman of HansCell; Member of the French National Academy of Technologies; authority in stem cell science
- Prof. Yong-Ming Wang (王永明) — Director of Sports Medicine, Peking University Third Hospital; expert in PRP/stem cell sports injury treatment
- Prof. Guo-Guang Zhao (赵国光) — President of Xuanwu Hospital, Capital Medical University; PI of iPSC Parkinson's clinical trial

3.5 Genetic Testing & Precision Medicine Products

Product / Service	Company	Technology Platform	Indication / Use	Regulatory Status	Price Range
Pan-Cancer Early Screening (OverC®)	Burning Rock	cfDNA Methylation + Mutation	6-9 cancer types early screening	Clinical validation / LDT	¥3,000-8,000
Pan-Cancer Early Screening (HaploX™)	HaploX	cfDNA WGS	Pan-cancer early screening	Clinical validation	¥5,000-10,000
MRD Monitoring (br PROPHET®)	Burning Rock	Tumor-informed ctDNA	Postoperative recurrence monitoring	Commercialized	¥8,000-15,000
520-Gene Tumor Panel	Geneseeq	NGS	Targeted therapy + immunotherapy guidance	LDT	¥5,000-12,000
Whole-Exome Sequencing (WES)	BGI	WES	Genetic disease diagnosis + tumor precision medicine	IVD / LDT	¥1,500-3,000
NIPT (NIFTY®)	BGI	NIPT	Trisomy 21, 18, 13 and chromosomal abnormalities	Approved	¥800-2,000

Pan-Cancer Early Screening (OverC®)	Burning Rock	cfDNA Methylation + Mutation	6-9 cancer types early screening	Clinical validation / LDT	¥3,000-8,000
Pan-Cancer Early Screening (HaploX™)	HaploX	cfDNA WGS	Pan-cancer early screening	Clinical validation	¥5,000-10,000
MRD Monitoring (br PROPHET®)	Burning Rock	Tumor-informed ctDNA	Postoperative recurrence monitoring	Commercialized	¥8,000-15,000
520-Gene Tumor Panel	Geneseeq	NGS	Targeted therapy + immunotherapy guidance	LDT	¥5,000-12,000
Whole-Exome Sequencing (WES)	BGI	WES	Genetic disease diagnosis + tumor precision medicine	IVD / LDT	¥1,500-3,000
NIPT (NIFTY®)	BGI	NIPT	Trisomy 21, 18, 13 and chromosomal abnormalities	Approved	¥800-2,000

Pan-Cancer Early Screening (OverC®)	Burning Rock	cfDNA Methylation + Mutation	6-9 cancer types early screening	Clinical validation / LDT	¥3,000-8,000
Pan-Cancer Early Screening (HaploX™)	HaploX	cfDNA WGS	Pan-cancer early screening	Clinical validation	¥5,000-10,000
MRD Monitoring (br PROPHET®)	Burning Rock	Tumor-informed ctDNA	Postoperative recurrence monitoring	Commercialized	¥8,000-15,000
520-Gene Tumor Panel	Geneseeq	NGS	Targeted therapy + immunotherapy guidance	LDT	¥5,000-12,000
Whole-Exome Sequencing (WES)	BGI	WES	Genetic disease diagnosis + tumor precision medicine	IVD / LDT	¥1,500-3,000
NIPT (NIFTY®)	BGI	NIPT	Trisomy 21, 18, 13 and chromosomal abnormalities	Approved	¥800-2,000

Pan-Cancer Early Screening (HaploX™)	HaploX	cfDNA WGS	Pan-cancer early screening	Clinical validation	¥5,000-10,000
MRD Monitoring (br PROPHET®)	Burning Rock	Tumor-informed ctDNA	Postoperative recurrence monitoring	Commercialized	¥8,000-15,000
520-Gene Tumor Panel	Geneseeq	NGS	Targeted therapy + immunotherapy guidance	LDT	¥5,000-12,000
Whole-Exome Sequencing (WES)	BGI	WES	Genetic disease diagnosis + tumor precision medicine	IVD / LDT	¥1,500-3,000
NIPT (NIFTY®)	BGI	NIPT	Trisomy 21, 18, 13 and chromosomal abnormalities	Approved	¥800-2,000

MRD Monitoring (br PROPHET®)	Burning Rock	Tumor-informed ctDNA	Postoperative recurrence monitoring	Commercialized	¥8,000-15,000
520-Gene Tumor Panel	Geneseeq	NGS	Targeted therapy + immunotherapy guidance	LDT	¥5,000-12,000
Whole-Exome Sequencing (WES)	BGI	WES	Genetic disease diagnosis + tumor precision medicine	IVD / LDT	¥1,500-3,000
NIPT (NIFTY®)	BGI	NIPT	Trisomy 21, 18, 13 and chromosomal abnormalities	Approved	¥800-2,000

520-Gene Tumor Panel	Geneseeq	NGS	Targeted therapy + immuno-therapy guidance	LDT	¥5,000-12,000
Whole-Exome Sequencing (WES)	BGI	WES	Genetic disease diagnosis + tumor precision medicine	IVD / LDT	¥1,500-3,000
NIPT (NIFTY®)	BGI	NIPT	Trisomy 21, 18, 13 and chromosomal abnormalities	Approved	¥800-2,000

Whole-Exome Sequencing (WES)	BGI	WES	Genetic disease diagnosis + tumor precision medicine	IVD / LDT	¥1,500-3,000
NIPT (NIFTY®)	BGI	NIPT	Trisomy 21, 18, 13 and chromosomal abnormalities	Approved	¥800-2,000

Recommended Institutions:

- BGI (华大基因) — Yantian District, Shenzhen; +86-755-3630-7000; www.bgi.com
- Burning Rock (燃石医学) — Guangzhou International Bio-Island; +86-20-3229-0808; www.burning-rock.com
- Geneseeq (世和基因) — Nanjing Jiangbei New District; +86-25-5816-5688; www.geneseeq.com
- HaploX (海普洛斯) — Shenzhen / Hangzhou; +86-755-8653-7699

3.6 Modernized Traditional Chinese Medicine Products (Marketed / Internationalized)

Product	Company	Indication	International Certification	Clinical Evidence
Lianhua Qingwen Capsule	Yiling Pharmaceutical	Influenza / Respiratory infections	FDA Phase II completed	Multiple RCTs published
Compound Danshen Dripping Pills	Tasly	Coronary heart disease angina	FDA Phase III completed	International multicenter trials
Guizhi Fuling Capsule	Kangyuan Pharmaceutical	Gynecological disorders	EU registration	Evidence-based medicine studies
Ginkgo Biloba Extract	Shushen / Multiple	Cognitive impairment	EMA review pending	Multiple clinical trials
Artemisinin-based Drugs	Kunming Pharma / Multiple	Malaria	WHO recommended	Nobel Prize-level evidence

Lianhua Qingwen Capsule	Yiling Pharmaceutical	Influenza / Respiratory infections	FDA Phase II completed	Multiple RCTs published
Compound Danshen Dripping Pills	Tasly	Coronary heart disease angina	FDA Phase III completed	International multicenter trials
Guizhi Fuling Capsule	Kangyuan Pharmaceutical	Gynecological disorders	EU registration	Evidence-based medicine studies
Ginkgo Biloba Extract	Shushen / Multiple	Cognitive impairment	EMA review pending	Multiple clinical trials
Artemisinin-based Drugs	Kunming Pharma / Multiple	Malaria	WHO recommended	Nobel Prize-level evidence

Lianhua Qingwen Capsule	Yiling Pharmaceutical	Influenza / Respiratory infections	FDA Phase II completed	Multiple RCTs published
Compound Danshen Dripping Pills	Tasly	Coronary heart disease angina	FDA Phase III completed	International multicenter trials
Guizhi Fuling Capsule	Kangyuan Pharmaceutical	Gynecological disorders	EU registration	Evidence-based medicine studies
Ginkgo Biloba Extract	Shushen / Multiple	Cognitive impairment	EMA review pending	Multiple clinical trials
Artemisinin-based Drugs	Kunming Pharma / Multiple	Malaria	WHO recommended	Nobel Prize-level evidence

Compound Danshen Dripping Pills	Tasly	Coronary heart disease angina	FDA Phase III completed	International multicenter trials
Guizhi Fuling Capsule	Kangyuan Pharmaceutical	Gynecological disorders	EU registration	Evidence-based medicine studies
Ginkgo Biloba Extract	Shushen / Multiple	Cognitive impairment	EMA review pending	Multiple clinical trials
Artemisinin-based Drugs	Kunming Pharma / Multiple	Malaria	WHO recommended	Nobel Prize-level evidence

Guizhi Fuling Capsule	Kangyuan Pharmaceutical	Gynecological disorders	EU registration	Evidence-based medicine studies
Ginkgo Biloba Extract	Shushen / Multiple	Cognitive impairment	EMA review pending	Multiple clinical trials
Artemisinin-based Drugs	Kunming Pharma / Multiple	Malaria	WHO recommended	Nobel Prize-level evidence

Ginkgo Biloba Extract	Shushen / Multiple	Cognitive impairment	EMA review pending	Multiple clinical trials
Artemisinin-based Drugs	Kunming Pharma / Multiple	Malaria	WHO recommended	Nobel Prize-level evidence

Recommended Institutions:

- Guang'anmen Hospital, China Academy of Chinese Medical Sciences — Beijing; +86-10-8800-1111; Prof. Hong-Sheng Lin (林洪生) — TCM Oncology

- Longhua Hospital, Shanghai University of TCM — Shanghai; +86-21-6438-5700; Prof. Jia-Xiang Liu (刘嘉湘)
- Guangdong Provincial Hospital of TCM — Guangzhou; +86-20-8188-7233; Prof. Zhong-De Zhang (张忠德) — "Uncle De," renowned TCM COVID-19 expert

Part 4: Key Medical Institutions & Contact Information

4.1 Oncology / Immunotherapy

Peking University Cancer Hospital

- Department: Lymphoma Department, GI Oncology Department
- Expert: Prof. Jun Zhu (朱军) — Lymphoma CAR-T therapy
- Address: No. 52 Fucheng Road, Haidian District, Beijing
- Phone: +86-10-8812-1122
- Website: www.bjcancer.org

Shanghai Jiao Tong University School of Medicine Affiliated Ruijin Hospital

- Department: Hematology (CAR-T Center)
- Expert: Prof. Wei-Li Zhao (赵维莅), Prof. Jian-Qing Mi (糜坚青)
- Address: No. 197 Ruijin Second Road, Shanghai
- Phone: +86-21-6437-0045
- Specialty: Leading CAR-T therapy for hematologic malignancies

Sun Yat-sen University Cancer Center

- Department: NPC Department, Hepatobiliary Surgery
- Expert: Prof. Jun Ma (马骏), Prof. Min-Shan Chen (陈敏山)
- Address: No. 651 Dongfeng East Road, Guangzhou
- Phone: +86-20-8734-3868
- Specialty: Global leader in nasopharyngeal carcinoma treatment

4.2 Stem Cell / Regenerative Medicine

Institute of Hematology, Chinese Academy of Medical Sciences (Tianjin)

- Department: Stem Cell Transplantation Center
- Expert: Prof. Jian-Xiang Wang (王建祥)
- Address: No. 288 Nanjing Road, Heping District, Tianjin
- Phone: +86-22-2390-9120

Peking University People's Hospital

- Department: Hematology Institute
- Expert: Prof. Xiao-Jun Huang (黄晓军) — Founder of the "Beijing Protocol" for haploidentical transplant
- Address: No. 11 Xizhimen South Street, Xicheng District, Beijing
- Phone: +86-10-8832-4466

4.3 Proton / Heavy-Ion Therapy

Shanghai Proton and Heavy Ion Center

- Department: Radiation Oncology
- Expert: Prof. Guo-Liang Jiang (蒋国梁), Prof. Jia-De Lu (陆嘉德)
- Address: No. 4365 Kangxin Highway, Pudong New Area, Shanghai
- Phone: +86-21-3829-6000
- Note: Requires pathology confirmation and MDT evaluation

Gansu Wuwei Tumor Hospital Heavy Ion Center

- Department: Heavy Ion Therapy Department
- Address: Wuwei City, Liangzhou District, Gansu Province
- Phone: +86-935-618-2000
- Specialty: China's first domestically developed heavy-ion device

4.4 Surgical Robots

Ruijin Hospital (Robotic Surgery Center)

- Department: Urology, General Surgery
- Expert: Prof. Bai-Yong Shen (沈柏用), Prof. Cheng-Hong Peng (彭承宏)

- Address: No. 197 Ruijin Second Road, Shanghai
- Phone: +86-21-6437-0045

West China Hospital, Sichuan University

- Department: Urology, Thoracic Surgery
- Expert: Prof. Qiang Wei (魏强), Prof. Lun-Xu Liu (刘伦旭)
- Address: No. 37 Guoxue Lane, Wuhou District, Chengdu
- Phone: +86-28-8542-2114

4.5 Traditional Chinese Medicine / Integrated Chinese-Western Medicine

Guang'anmen Hospital, China Academy of Chinese Medical Sciences

- Department: Oncology Department, Endocrinology Department, Acupuncture Department
- Expert: Prof. Hong-Sheng Lin (林洪生) — TCM Oncology; Prof. Qing Ni (倪青) — Diabetes
- Address: No. 5 Beixiange, Xicheng District, Beijing
- Phone: +86-10-8800-1111

Longhua Hospital, Shanghai University of Traditional Chinese Medicine

- Department: Oncology Department, Orthopedics Department
- Expert: Prof. Jia-Xiang Liu (刘嘉湘), Prof. Qi Shi (施杞)
- Address: No. 725 Wanping South Road, Xuhui District, Shanghai
- Phone: +86-21-6438-5700

4.6 Genetic Testing / Precision Medicine

BGI (华大基因)

- Services: Whole-genome sequencing, tumor genetic testing
- Address: Beishan Industrial Zone, Yantian District, Shenzhen
- Phone: +86-755-3630-7000
- Website: www.bgi.com

Burning Rock (燃石医学)

- Services: Tumor genetic testing, MRD monitoring
- Address: Guangzhou International Bio-Island
- Phone: +86-20-3229-0808
- Website: www.burning-rock.com

Part 5: Recommended High-End Services for MediEscortChina

Based on the cross-analysis of Placidway international popular services and China's medical breakthroughs, the following high-end services are recommended to be added to MediEscortChina's existing 370-item catalog:

Service	Reference Price (RMB)	Target Clients	Partner Hospitals
CAR-T Cell Therapy Full-Course Management	¥1,200,000 – 1,500,000	Hematologic malignancy patients	Ruijin / Peking University People's Hospital
Proton / Heavy-Ion Radiotherapy	¥270,000 – 380,000	Solid tumor patients	Shanghai Proton / Wuwei Heavy Ion
Da Vinci / Domestic Robotic Surgery	¥50,000 – 150,000	Minimally invasive surgery candidates	West China / Ruijin
Whole-Genome Precision Health Screening	¥15,000 – 30,000	Premium wellness clients	BGI
Stem Cell Knee Repair	¥30,000 – 60,000	Degenerative arthritis patients	Tertiary hospitals
Integrated Chinese-Western Oncology Rehabilitation	¥5,000 – 20,000	Post-operative cancer patients	Guang'anmen / Longhua
5G Remote Expert Consultation + Robotic Surgery	¥20,000 – 50,000	Complex cases requiring top-tier expertise	Multi-center
Personalized Cancer Vaccine (Neoantigen)	¥100,000 – 300,000	High-risk / recurrent cancer patients	Clinical trials

CAR-T Cell Therapy Full-Course Management	¥1,200,000 – 1,500,000	Hematologic malignancy patients	Ruijin / Peking University People's Hospital
Proton / Heavy-Ion Radiotherapy	¥270,000 – 380,000	Solid tumor patients	Shanghai Proton / Wuwei Heavy Ion
Da Vinci / Domestic Robotic Surgery	¥50,000 – 150,000	Minimally invasive surgery candidates	West China / Ruijin
Whole-Genome Precision Health Screening	¥15,000 – 30,000	Premium wellness clients	BGI
Stem Cell Knee Repair	¥30,000 – 60,000	Degenerative arthritis patients	Tertiary hospitals
Integrated Chinese-Western Oncology Rehabilitation	¥5,000 – 20,000	Post-operative cancer patients	Guang'anmen / Longhua
5G Remote Expert Consultation + Robotic Surgery	¥20,000 – 50,000	Complex cases requiring top-tier expertise	Multi-center
Personalized Cancer Vaccine (Neoantigen)	¥100,000 – 300,000	High-risk / recurrent cancer patients	Clinical trials

CAR-T Cell Therapy Full-Course Management	¥1,200,000 – 1,500,000	Hematologic malignancy patients	Ruijin / Peking University People's Hospital
Proton / Heavy-Ion Radiotherapy	¥270,000 – 380,000	Solid tumor patients	Shanghai Proton / Wuwei Heavy Ion
Da Vinci / Domestic Robotic Surgery	¥50,000 – 150,000	Minimally invasive surgery candidates	West China / Ruijin
Whole-Genome Precision Health Screening	¥15,000 – 30,000	Premium wellness clients	BGI
Stem Cell Knee Repair	¥30,000 – 60,000	Degenerative arthritis patients	Tertiary hospitals
Integrated Chinese-Western Oncology Rehabilitation	¥5,000 – 20,000	Post-operative cancer patients	Guang'anmen / Longhua
5G Remote Expert Consultation + Robotic Surgery	¥20,000 – 50,000	Complex cases requiring top-tier expertise	Multi-center
Personalized Cancer Vaccine (Neoantigen)	¥100,000 – 300,000	High-risk / recurrent cancer patients	Clinical trials

Proton / Heavy-Ion Radiotherapy	¥270,000 – 380,000	Solid tumor patients	Shanghai Proton / Wuwei Heavy Ion
Da Vinci / Domestic Robotic Surgery	¥50,000 – 150,000	Minimally invasive surgery candidates	West China / Ruijin
Whole-Genome Precision Health Screening	¥15,000 – 30,000	Premium wellness clients	BGI
Stem Cell Knee Repair	¥30,000 – 60,000	Degenerative arthritis patients	Tertiary hospitals
Integrated Chinese-Western Oncology Rehabilitation	¥5,000 – 20,000	Post-operative cancer patients	Guang'anmen / Longhua
5G Remote Expert Consultation + Robotic Surgery	¥20,000 – 50,000	Complex cases requiring top-tier expertise	Multi-center
Personalized Cancer Vaccine (Neoantigen)	¥100,000 – 300,000	High-risk / recurrent cancer patients	Clinical trials

Da Vinci / Domestic Robotic Surgery	¥50,000 – 150,000	Minimally invasive surgery candidates	West China / Ruijin
Whole-Genome Precision Health Screening	¥15,000 – 30,000	Premium wellness clients	BGI
Stem Cell Knee Repair	¥30,000 – 60,000	Degenerative arthritis patients	Tertiary hospitals
Integrated Chinese-Western Oncology Rehabilitation	¥5,000 – 20,000	Post-operative cancer patients	Guang'anmen / Longhua
5G Remote Expert Consultation + Robotic Surgery	¥20,000 – 50,000	Complex cases requiring top-tier expertise	Multi-center
Personalized Cancer Vaccine (Neoantigen)	¥100,000 – 300,000	High-risk / recurrent cancer patients	Clinical trials

Whole-Genome Precision Health Screening	¥15,000 – 30,000	Premium wellness clients	BGI
Stem Cell Knee Repair	¥30,000 – 60,000	Degenerative arthritis patients	Tertiary hospitals
Integrated Chinese-Western Oncology Rehabilitation	¥5,000 – 20,000	Post-operative cancer patients	Guang'anmen / Longhua
5G Remote Expert Consultation + Robotic Surgery	¥20,000 – 50,000	Complex cases requiring top-tier expertise	Multi-center
Personalized Cancer Vaccine (Neoantigen)	¥100,000 – 300,000	High-risk / recurrent cancer patients	Clinical trials

Stem Cell Knee Repair	¥30,000 – 60,000	Degenerative arthritis patients	Tertiary hospitals
Integrated Chinese-Western Oncology Rehabilitation	¥5,000 – 20,000	Post-operative cancer patients	Guang'anmen / Longhua
5G Remote Expert Consultation + Robotic Surgery	¥20,000 – 50,000	Complex cases requiring top-tier expertise	Multi-center
Personalized Cancer Vaccine (Neoantigen)	¥100,000 – 300,000	High-risk / recurrent cancer patients	Clinical trials

Integrated Chinese-Western Oncology Rehabilitation	¥5,000 – 20,000	Post-operative cancer patients	Guang'anmen / Longhua
5G Remote Expert Consultation + Robotic Surgery	¥20,000 – 50,000	Complex cases requiring top-tier expertise	Multi-center
Personalized Cancer Vaccine (Neoantigen)	¥100,000 – 300,000	High-risk / recurrent cancer patients	Clinical trials

5G Remote Expert Consultation + Robotic Surgery	¥20,000 – 50,000	Complex cases requiring top-tier expertise	Multi-center
Personalized Cancer Vaccine (Neoantigen)	¥100,000 – 300,000	High-risk / recurrent cancer patients	Clinical trials

Report Prepared by: MediEscortChina Research Division

Data Current as of: June 2025

Contact: +86-155-2777-1775 | www.MediEscortChina.com

Disclaimer: All pricing information in this report is for reference only. Actual costs vary by hospital, physician, and individual patient condition. Please confirm directly with the treating institution for final pricing. Product availability and regulatory status are subject to change.